StockData
BioMarin Pharmaceutical Inc logo

BioMarin Pharmaceutical Inc (BMRN) stock

BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3093% above fair value
$58.51+0.52 (+0.90%)

Close on Nov 17, 2026Market cap $11.33BP/E 154.0Yield –

BioMarin Pharmaceutical cash

Cash and short-term investments held at the end of each period.

BioMarin Pharmaceutical's cash was $874.01M at Jun 30, 2026. For fiscal 2025 it was $1.56B, up 37.2% from the year before. Over ten years it grew 10.2% a year on average. The highest annual figure on record is $1.56B in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.56B+37.2%
FY2024Dec 31, 2024$1.14B+6.0%
FY2023Dec 31, 2023$1.07B-16.9%
FY2022Dec 31, 2022$1.29B+27.4%
FY2021Dec 31, 2021$1.01B-4.8%
FY2020Dec 31, 2020$1.07B+41.3%
FY2019Dec 31, 2019$753.81M-30.5%
FY2018Dec 31, 2018$1.08B-22.3%
FY2017Dec 31, 2017$1.40B+76.8%
FY2016Dec 31, 2016$789.68M+33.3%
FY2015Dec 31, 2015$592.62M-37.3%
FY2014Dec 31, 2014$945.19M+20.4%
FY2013Dec 31, 2013$784.72M+75.2%
FY2012Dec 31, 2012$447.81M+129.5%
FY2011Dec 31, 2011$195.09M-28.8%
FY2010Dec 31, 2010$274.11M-8.8%
FY2009Dec 31, 2009$300.68M+34.9%
FY2008Dec 31, 2008$222.90M-2.4%
FY2007Dec 31, 2007$228.34M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$874.01M-39.0%
Q1 FY2026Mar 31, 2026$2.22B+74.7%
Q4 FY2025Dec 31, 2025$1.56B+37.2%
Q3 FY2025Sep 30, 2025$1.48B+58.8%
Q2 FY2025Jun 30, 2025$1.43B+17.0%
Q1 FY2025Mar 31, 2025$1.27B+21.6%
Q4 FY2024Dec 31, 2024$1.14B+6.0%
Q3 FY2024Sep 30, 2024$930.44M-17.4%
Q2 FY2024Jun 30, 2024$1.22B+4.6%
Q1 FY2024Mar 31, 2024$1.05B-9.2%
Q4 FY2023Dec 31, 2023$1.07B-16.9%
Q3 FY2023Sep 30, 2023$1.13B-11.6%
Q2 FY2023Jun 30, 2023$1.17B+5.5%
Q1 FY2023Mar 31, 2023$1.15B+9.1%
Q4 FY2022Dec 31, 2022$1.29B+27.4%
Q3 FY2022Sep 30, 2022$1.27B+18.0%
Q2 FY2022Jun 30, 2022$1.11B-1.2%
Q1 FY2022Mar 31, 2022$1.06B-2.9%
Q4 FY2021Dec 31, 2021$1.01B-4.8%
Q3 FY2021Sep 30, 2021$1.08B-28.3%
Q2 FY2021Jun 30, 2021$1.12B-18.6%
Q1 FY2021Mar 31, 2021$1.09B+26.7%
Q4 FY2020Dec 31, 2020$1.07B+41.3%
Q3 FY2020Sep 30, 2020$1.51B+108.9%
Q2 FY2020Jun 30, 2020$1.38B+88.8%
Q1 FY2020Mar 31, 2020$858.40M-4.1%
Q4 FY2019Dec 31, 2019$753.81M-30.5%
Q3 FY2019Sep 30, 2019$720.79M-50.1%
Q2 FY2019Jun 30, 2019$731.10M-46.4%
Q1 FY2019Mar 31, 2019$894.85M-35.3%
Q4 FY2018Dec 31, 2018$1.08B-22.3%
Q3 FY2018Sep 30, 2018$1.44B+14.8%
Q2 FY2018Jun 30, 2018$1.36B+87.3%
Q1 FY2018Mar 31, 2018$1.38B+103.9%
Q4 FY2017Dec 31, 2017$1.40B+76.8%
Q3 FY2017Sep 30, 2017$1.26B+21.5%
Q2 FY2017Jun 30, 2017$727.78M–
Q1 FY2017Mar 31, 2017$678.06M–
Q4 FY2016Dec 31, 2016$789.68M–
Q3 FY2016Sep 30, 2016$1.03B–

More BioMarin Pharmaceutical figures

See a number that looks wrong?